Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 7/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | FADS1 | O60427 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2896757 | 1.00 | GRM2 (0.56) | GRM2HRH3FADS1LTA4HMEN1 | |
| SCHEMBL2893019 | 0.92 | GRM2 (0.51) | GRM2HRH3FADS1LTA4HMEN1 | |
| SCHEMBL2893022 | 0.92 | GRM2 (0.51) | GRM2HRH3FADS1LTA4HMEN1 | |
| SCHEMBL2892125 | 0.90 | GRM2 (0.57) | GRM2HRH3FADS1LTA4HHTR2A | |
| SCHEMBL4329682 | 0.90 | GRM2 (0.57) | GRM2HRH3FADS1LTA4HHTR2A | |
| SCHEMBL2899151 | 0.88 | GRM2 (0.48) | GRM2FADS1LTA4H | |
| SCHEMBL2899150 | 0.88 | GRM2 (0.48) | GRM2FADS1LTA4H | |
| SCHEMBL2895933 | 0.88 | GRM2 (0.55) | GRM2FADS1LTA4HHTR2A | |
| SCHEMBL5478198 | 0.88 | GRM2 (0.58) | GRM2FADS1LTA4HMEN1KMT2A | |
| SCHEMBL2898095 | 0.88 | GRM2 (0.58) | GRM2FADS1LTA4HMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | claimed |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM2 | GRM2 3/4885HRH3 650/4885FADS1 4353/4885 |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | GRM2 3/4885HRH3 650/4885FADS1 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.